Opinion

Video

Empowering Pharmacists: Essential Insights for HE Management

Author(s):

Arun Jesudian, MD,Ralph J. Riello, PharmD, BCPS

Key opinion leaders highlight essential considerations for pharmacists, including medication costs, staying current with the latest advancements and clinical trials in hepatic encephalopathy (HE), and understanding the incidence of the disease.

Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
fda approved label. fda approved red band sign. fda approved - Image credit: Aquir | stock.adobe.com
December 18th 2024

Ustekinumab-stba Receives FDA Approval for Autoimmune Disorder and Inflammatory Bowel Disease

Kennedy Ferruggia, Assistant Editor
Are OTC Proton Pump Inhibitors a Boon Or a Curse?
September 5th 2024

Are OTC Proton Pump Inhibitors a Boon Or a Curse?

Madison Gill, PharmD Candidate Allyson Gill, PharmD Candidate Ajay Sharma, PhD, RPh, MPharm, PGDCR Khemraj Hirani, PhD, RPh, MBA, MPharm, RAC, CIP, CCRP
Crohn's disease or ulcerative colitis concept. Doctor counseling male patient with abdominal pain in hospital examination room - Image credit: Witoon | stock.adobe.com
August 8th 2024

RHB-104 Plus Standard of Care Offers Extended Treatment for Crohn Disease

Kennedy Ferruggia, Assistant Editor
Skeletal structure of Esomeprazole proton pump inhibitor for peptic ulcers
July 12th 2024

Heterogeneity Observed in Reporting on Drug-Drug Interactions With Proton Pump Inhibitors

Luke Halpern, Assistant Editor
orange peels and heart health/Image Credit: © Kseniia - stock.adobe.com
June 18th 2024

Exploring the Connection Between Orange Peels, Gut Metabolism, and Heart Health

Alexandra Gerlach, Associate Editor
Image credit: sdecoret | stock.adobe.com
April 19th 2024

FDA Approves Vedolizumab for Maintenance Therapy to Treat Crohn Disease

Kennedy Ferruggia, Assistant Editor